Pacritinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 226 publications

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Journal: Expert review of hematology
Published: June 19, 2026

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation
Published: May 05, 2026

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

Journal: Leukemia & lymphoma
Published: April 15, 2026

Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.

Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.

Journal: Frontiers in oncology
Published: April 09, 2026

A pharmacological profile of pacritinib for the treatment of myelofibrosis.

A pharmacological profile of pacritinib for the treatment of myelofibrosis.

Journal: Expert review of clinical pharmacology
Published: April 08, 2026

Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?

Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?

Journal: Expert opinion on investigational drugs
Published: March 11, 2026

JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions.

JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions.

Journal: Cancers
Published: January 08, 2026

Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data.

Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data.

Journal: Clinical pharmacology in drug development
Published: January 05, 2026

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.

Journal: Expert review of hematology
Published: December 14, 2025

Pacritinib in patients with myelodysplastic/myeloproliferative neoplasms.

Pacritinib in patients with myelodysplastic/myeloproliferative neoplasms.

Journal: Leukemia & lymphoma
Published: November 26, 2025

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.

Journal: Journal of clinical medicine
Published: November 16, 2025

Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?

Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?

Journal: Future oncology (London, England)
Published: November 04, 2025
Showing 1-12 of 226

Last Updated: 06/30/2026